Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Danone
  6. News
  7. Summary
    BN   FR0000120644

DANONE

(BN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Activist investor Bluebell takes stake in GSK

09/22/2021 | 01:03pm EDT
FILE PHOTO: A GlaxoSmithKline plant is seen in Montrose, Scotland, Britain

(Reuters) -Activist investor Bluebell Capital Partners has taken a stake worth about 10 million euros in British pharmaceuticals group GlaxoSmithKline in efforts to shake up top management, a Financial Times report https://www.ft.com/content/539c077d-6ac2-4e79-9e0f-8080a31c5530 said on Wednesday.

Bluebell said in a letter to GSK Chairman Jonathan Symonds that chief executive Emma Walmsley should reapply for her job as she would have "renewed credibility both internally and externally", the FT report said.

Earlier this year, activist Elliott had also taken a stake in GSK, calling for a leadership change at the company. Bluebell was largely backing Elliott's demands, the FT said.

GSK confirmed Bluebell had made demands in a letter.

"We continue to engage extensively with our shareholders with over 500 meetings so far this year," GSK said in a statement.

"They have expressed widespread and strong support for our plans to deliver a step-change in growth and performance, and given clear direction to focus on execution," the company added.

The British pharma major, with a market value of over 71 billion pounds ($96.95 billion), in July rejected Elliott's demands to change its board and sell its consumer healthcare arm.

GSK has set out plans to turn its consumer healthcare arm into a separately listed company, in a move that will deliver an 8 billion pound windfall and other financial benefits to boost drug development at its underperforming pharma business.

Bluebell was part of a successful investor campaign to oust Danone chairman and chief executive Emmanuel Faber in March.

($1 = 0.7323 pounds)

(Reporting by Aditi Sebastian in Bengaluru and Ludwig Burger in Frankfurt. Editing by Jane Merriman)


© Reuters 2021
All news about DANONE
10/20EUROPE : European stocks hit 6-week highs as Nestle shines in mixed bag of earnings
RE
10/20DANONE : Goldman Sachs reiterates its Sell rating
MD
10/20Inflation trade? Nestle reaps benefits from higher prices
RE
10/20DANONE : Receives a Buy rating from Kepler Cheuvreux
MD
10/20DANONE : Goldman Sachs keeps a Sell rating
MD
10/20DANONE : Jefferies reiterates its Buy rating
MD
10/20European stocks hit 6-week highs as Nestle shines in mixed bag of earnings
RE
10/20DANONE : UBS maintains a Sell rating
MD
10/20EMEA MORNING BRIEFING : Hawkish Fed Tilt to Drag on Stocks
DJ
10/19ADRs End Higher; Ericsson, Danone Among Companies Actively Trading
DJ
More news
Analyst Recommendations on DANONE
More recommendations
Financials
Sales 2021 23 872 M 27 843 M 27 843 M
Net income 2021 1 939 M 2 261 M 2 261 M
Net Debt 2021 10 720 M 12 503 M 12 503 M
P/E ratio 2021 18,0x
Yield 2021 3,45%
Capitalization 36 832 M 42 887 M 42 958 M
EV / Sales 2021 1,99x
EV / Sales 2022 1,90x
Nbr of Employees 100 383
Free-Float 92,0%
Chart DANONE
Duration : Period :
Danone Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DANONE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Last Close Price 56,59 €
Average target price 61,62 €
Spread / Average Target 8,89%
EPS Revisions
Managers and Directors
Antoine Bernard de Saint-Affrique Chief Executive Officer
Juergen Esser Chief Financial, Technology & Data Officer
Gilles Schnepp Non-Executive Chairman
Domitille Doat-Le Bigot Chief Digital Officer
Jean-Michel Sévérino Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DANONE5.26%42 115
NESTLÉ S.A.8.34%337 012
MONDELEZ INTERNATIONAL, INC.3.11%83 576
YIHAI KERRY ARAWANA HOLDINGS CO., LTD-42.84%53 046
THE KRAFT HEINZ COMPANY6.52%45 033
GENERAL MILLS, INC.6.65%37 365